Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Jan. 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0750196/Atherosclerosis-or-Coronary-Artery-Disease-CAD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Introduction 7
2.1 Overview 7
2.2 Types of Atherosclerosis 7
2.3 Epidemiology 8
2.4 Etiology 9
2.4.1 Cells and Lipids 9
2.4.2 ECM (Extracellular Matrix) 9
2.4.3 Endothelial Injury as the Mechanism of Atherosclerosis 9
2.4.4 Role of Low-Density Lipoprotein-Oxidative Stress 9
2.4.5 Risk Factors 10
2.5 Symptoms 11
2.6 Diagnosis 12
2.7 Pathophysiology 14
2.7.1 Pathological Pathway for Atherosclerosis 15
2.8 Treatment and Management Pattern 15
2.8.1 HMG-CoA Reductase Inhibitors 15
2.8.2 ACE Inhibitors 15
2.8.3 Beta Blockers 16
2.8.4 Omega-3 Fatty Acids 16
2.8.5 Aldosterone Antagonists 16
2.8.6 Calcium Channel Blockers 16
2.8.7 Nicotinic Acid Derivatives 16
2.8.8 Fibric Acid Derivatives 16
2.8.9 Platelet Aggregation Inhibitors 16
2.8.10 Therapeutic Lifestyle Changes (TLC) 16
2.9 GlobalData Pipeline Report Guidance 19
3 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Market Characterization 20
3.1 Atherosclerosis or CAD Therapeutics Market Size (2005-2010) - Global 20
3.2 Atherosclerosis or CAD Therapeutics Market Forecast (2010-2018) - Global 21
3.3 Atherosclerosis or CAD Therapeutics Market - The US (2005-2010) 22
3.4 Atherosclerosis or CAD Therapeutics Market Forecast - The US (2010-2018) 23
3.5 Atherosclerosis or CAD Therapeutics Market - France (2005-2010) 24
3.6 Atherosclerosis or CAD Therapeutics Market Forecast - France (2010-2018) 25
3.7 Atherosclerosis or CAD Therapeutics Market - Germany (2005-2010) 26
3.8 Atherosclerosis or CAD Therapeutics Market Forecast - Germany (2010-2018) 27
3.9 Atherosclerosis or CAD Therapeutics Market - Italy (2005-2010) 28
3.10 Atherosclerosis or CAD Therapeutics Market Forecast - Italy (2010-2018) 29
3.11 Atherosclerosis or CAD Therapeutics Market - Spain (2005-2010) 30
3.12 Atherosclerosis or CAD Therapeutics Market Forecast - Spain (2010-2018) 31
3.13 Atherosclerosis or CAD Therapeutics Market - The UK (2005-2010) 32
3.14 Atherosclerosis or CAD Therapeutics Market Forecast - The UK (2010-2018) 33
3.15 Atherosclerosis or CAD Therapeutics Market - Japan (2005-2010) 34
3.16 Atherosclerosis or CAD Therapeutics Market Forecast - Japan (2010-2018) 35
3.17 Drivers and Barriers for the Atherosclerosis or CAD Therapeutics Market 36
3.17.1 Atherosclerosis or CAD Therapeutics Market Drivers 36
3.17.2 Atherosclerosis or CAD Therapeutics Market Barriers 36
3.18 Opportunity and Unmet Need 37
3.19 Key Takeaway 38
4 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Competitive Assessment 39
4.1 Overview 39
4.2 Strategic Competitor Assessment 39
4.3 Product Profile for the Major Products in Atherosclerosis or CAD Market 40
4.3.1 Lipitor (atorvastatin calcium) 40
4.3.2 Crestor (rosuvastatin calcium) 42
4.3.3 Plavix (clopidogrel bisulfate) 43
4.3.4 Altace (ramipril) 44
4.3.5 Norvasc (amlodipine) 45
4.3.6 Niaspan (nicotinic acid) 46
4.4 Key Takeaway 47
5 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment 48
5.1 Overview 48
5.2 Strategic Pipeline Assessment 48
5.3 Atherosclerosis or CAD Therapeutics Market - Pipeline Assessment by Phase of Development 48
5.3.1 Atherosclerosis or CAD Therapeutics - Phase III Pipeline 48
5.3.2 Atherosclerosis or CAD Therapeutics - Phase II Pipeline 49
5.3.3 Atherosclerosis or CAD Therapeutics - Phase I Clinical Pipeline 50
5.3.4 Atherosclerosis or CAD Therapeutics - Preclinical Pipeline 50
5.3.5 Atherosclerosis or CAD Therapeutics - Discovery Pipeline 51
5.4 Atherosclerosis or CAD Therapeutics - Pipeline by Mechanism of Action 51
5.5 Technology Trends Analytical Framework 53
5.6 Atherosclerosis or CAD Therapeutics Market - Most Promising Drugs under Clinical Development 54
5.7 Most Promising Drug Profiles 55
5.7.1 Anacetrapib (MK- 0859) 55
5.7.2 Darapladib 56
5.7.3 Dalcetrapib (RG1658) 57
5.7.4 Mipomersen 58
5.7.5 Varespladib (A-002) 59
5.7.6 MK-0524B 60
5.7.7 Aleglitazar (RG1439) 61
5.7.8 Vorapaxar 62
5.7.9 Aliskiren 63
5.7.10 Canakinumab (ACZ885) 64
5.7.11 Generx 64
5.7.12 Cangrelor 65
5.7.13 Otamixaban 66
5.7.14 Xarelto (rivaroxaban) 67
5.8 Key Takeaway 68
6 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Clinical Trials Mapping 69
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 69
6.2 Clinical Trials by Phase of Clinical Development 70
6.3 Clinical Trials by Trial Status 71
6.4 Prominent Sponsors 72
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 74
7 Coronary Artery Disease (CAD) Therapeutics - Strategic Assessment 75
7.1 Key Events Impacting the Future Market 75
7.2 Future Market Competition Scenario 76
8 Coronary Artery Disease (CAD) Therapeutics - Future Players 78
8.1 Introduction 78
8.2 Company Profiles 78
8.2.1 GlaxoSmithKline Plc 78
8.2.2 Merck & Co., Inc. 80
8.2.3 F Hoffmann La Roche 82
8.2.4 ISIS Pharmaceuticals 82
8.2.5 Anthera Pharmaceuticals 83
8.2.6 Novartis A G 84
8.2.7 Sanofi 85
8.2.8 Johnson & Johnson 86
8.2.9 Bayer AG 87
8.2.10 Cardium Therapeutics 88
8.2.11 The Medicines Company 90
8.2.12 Tabular Presentation Details of Other Companies in the Pipeline 91
8.2.13 Key Takeaway 97
9 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Licensing & Partnership Deals 98
10 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Appendix 103
10.1 Market Definitions 103
10.2 Acronyms 103
10.3 Methodology 106
10.3.1 Coverage 107
10.3.2 Secondary Research 107
10.3.3 Forecasting 107
10.3.4 Primary Research 109
10.3.5 Expert Panel Validation 110
10.4 Contact Us 110
10.5 Disclaimer 110
10.6 Bibliography 111
List of Tables
Table 1: Atherosclerosis or CAD Therapeutics - Modified AHA Consensus Classification Based on Morphologic Descriptions* 8
Table 2: Atherosclerosis or CAD Therapeutics - NCEP ATP III Classification of Cholesterol and Triglyceride Levels 13
Table 3: Atherosclerosis or CAD Therapeutics - ATP III LDL-C Goals and Outpoints for Therapeutics Lifestyle Changes and Drug Therapy in Different Risk Categories 17
Table 4: Atherosclerosis or CAD Therapeutics Market, Global, Revenue ($bn), 2005-2010 20
Table 5: Atherosclerosis or CAD Therapeutics Market, Global, Forecast ($bn), 2010-2018 21
Table 6: Atherosclerosis or CAD Therapeutics Market, The US, Forecast ($bn), 2005-2010 22
Table 7: Atherosclerosis or CAD Therapeutics Market, The US, Forecast ($bn), 2010-2018 23
Table 8: Atherosclerosis or CAD Therapeutics Market, France, Revenue ($m), 2005-2010 24
Table 9: Atherosclerosis or CAD Therapeutics Market, France, Forecast ($m), 2010-2018 25
Table 10: Atherosclerosis or CAD Therapeutics Market, Germany, Revenue ($bn), 2005-2010 26
Table 11: Atherosclerosis or CAD Therapeutics Market, Germany, Forecast ($bn), 2010-2018 27
Table 12: Atherosclerosis or CAD Therapeutics Market, Italy, Revenue ($m), 2005-2010 28
Table 13: Atherosclerosis or CAD Therapeutics Market, Italy, Forecast ($m), 2010-2018 29
Table 14: Atherosclerosis or CAD Therapeutics Market, Spain, Revenue ($m), 2005-2010 30
Table 15: Atherosclerosis or CAD Therapeutics Market, Spain, Forecast ($m), 2010-2018 31
Table 16: Atherosclerosis or CAD Therapeutics Market, The UK, Revenue ($m), 2005-2010 32
Table 17: Atherosclerosis or CAD Therapeutics Market, The UK, Forecast ($m), 2010-2018 33
Table 18: Atherosclerosis or CAD Therapeutics Market, Japan, Revenue ($m), 2005-2010 34
Table 19: Atherosclerosis or CAD Therapeutics Market, Japan, Forecast ($m), 2010-2018 35
Table 20: Atherosclerosis or CAD Therapeutics - Phase III Pipeline, 2011 48
Table 21: Atherosclerosis or CAD Therapeutics - Phase II Pipeline, 2011 49
Table 22: Atherosclerosis or CAD Therapeutics - Phase I Pipeline, 2011 50
Table 23: Atherosclerosis or CAD Therapeutics - Preclinical Pipeline, 2011 50
Table 24: Atherosclerosis or CAD Therapeutics - Discovery Pipeline, 2011 51
Table 25: Atherosclerosis or CAD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 54
Table 26: Atherosclerosis or CAD Therapeutics - Clinical Trials by Country, 2011 69
Table 27: Atherosclerosis or CAD Therapeutics, Major Markets - Clinical Trials by Phase, 2011 70
Table 28: Atherosclerosis or CAD Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 71
Table 29: Atherosclerosis or CAD Therapeutics, Major Markets, Overall Sponsors, 2011 72
Table 30: Atherosclerosis or CAD Therapeutics, Major Markets, Prominent Sponsors, 2011 73
Table 31: Atherosclerosis or CAD Therapeutics - Companies Participating in Clinical Trials, 2011 74
Table 32: GlaxoSmithKline Pipeline Products 79
Table 33: Merck Pipeline Products 81
Table 34: Pipeline Products 83
Table 35: Anthera Pharmaceuticals Company Pipeline Products 83
Table 36: Novartis A G Company Pipeline Products 85
Table 37: Sanofi - CAD Pipeline Products, 2011 86
Table 38: Johnson and Johnson Company - CAD Pipeline Products, 2011 86
Table 39: Bayer AG - CAD Pipeline Products, 2011 88
Table 40: Cardium Therapeutics, Inc., Product pipeline 2011 89
Table 41: Product pipeline 2011 91
Table 42: Other Companies in Pipeline, CAD Therapeutics, 2011 91
Table 43: CAD Therapeutics, Global, Deals, 2011 98
List of Figures
Figure 1: Atherosclerosis or CAD Therapeutics - Endothelial Dysfunction 11
Figure 2: Stages in Development of Atherosclerosis Lesion 14
Figure 3: Atherosclerosis or CAD Therapeutics - Pathology 18
Figure 4: Atherosclerosis or CAD Therapeutics Market, Global, Revenue ($bn), 2005-2010 20
Figure 5: Atherosclerosis or CAD Therapeutics Market, Global, Forecast ($bn), 2010-2018 21
Figure 6: Atherosclerosis or CAD Therapeutics Market, The US, Revenue ($bn), 2005-2010 22
Figure 7: Atherosclerosis or CAD Therapeutics Market, The US, Forecast ($bn), 2010-2018 23
Figure 8: Atherosclerosis or CAD Therapeutics Market, France, Revenue ($m), 2005-2010 24
Figure 9: Atherosclerosis or CAD Therapeutics Market, France, Forecast ($m), 2010-2018 25
Figure 10: Atherosclerosis or CAD Therapeutics Market, Germany, Revenue ($bn), 2005-2010 26
Figure 11: Atherosclerosis or CAD Therapeutics Market, Germany, Forecast ($bn), 2010-2018 27
Figure 12: Atherosclerosis or CAD Therapeutics Market, Italy, Revenue ($m), 2005-2010 28
Figure 13: Atherosclerosis or CAD Therapeutics Market, Italy, Forecast ($m), 2010-2018 29
Figure 14: Atherosclerosis or CAD Therapeutics Market, Spain, Revenue ($m), 2005-2010 30
Figure 15: Atherosclerosis or CAD Therapeutics Market, Spain, Forecast ($m), 2010-2018 31
Figure 16: Atherosclerosis or CAD Therapeutics Market, The UK, Revenue ($m), 2005-2010 32
Figure 17: Atherosclerosis or CAD Therapeutics Market, The UK, Forecast ($m), 2010-2018 33
Figure 18: Atherosclerosis or CAD Therapeutics Market, Japan, Revenue ($m), 2005-2010 34
Figure 19: Atherosclerosis or CAD Therapeutics Market, Japan, Forecast ($m), 2010-2018 35
Figure 20: Opportunity and Unmet Need in the Atherosclerosis or CAD Therapeutics Market, 2011 37
Figure 21: Atherosclerosis or CAD Therapeutics - Strategic Competitor Assessment, 2011 40
Figure 22: Atherosclerosis or CAD Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 52
Figure 23: Atherosclerosis or CAD Therapeutics Market - Pipeline by Phase of Development, 2011 52
Figure 24: Atherosclerosis or CAD Therapeutics Market Technology Trends Analytics Framework, 2011 53
Figure 25: Atherosclerosis or CAD Therapeutics - Technology Trends Analytics Framework - Description, 2011 54
Figure 26: Atherosclerosis or CAD Therapeutics - Clinical Trials by Country, 2011 69
Figure 27: Atherosclerosis or CAD Therapeutics, Major Markets - Clinical Trials by Phase, 2011 70
Figure 28: Atherosclerosis or CAD Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 71
Figure 29: Atherosclerosis or CAD Therapeutics, Overall Sponsors, 2011 72
Figure 30: Atherosclerosis or CAD Therapeutics, Major Markets, Prominent Sponsors (%), 2011 73
Figure 31: Atherosclerosis or CAD Therapeutics, Clinical Trials of Top Ten Companies by Phase, 2011 74
Figure 32: Atherosclerosis or CAD Therapeutics Market, Drivers and Barriers 2011 75
Figure 33: Implications for Future Market Competition in the Atherosclerosis or CAD Therapeutics Market, 2011 76
Figure 34: Atherosclerosis or CAD Therapeutics Market - Clinical Pipeline by Company, 2011 78
Figure 35: GlobalData Market Forecasting Model 109
Companies mentioned
GlaxoSmithKline Plc
Merck & Co., Inc.
F Hoffmann La Roche
ISIS Pharmaceuticals
Anthera Pharmaceuticals
Novartis A G
Sanofi
Johnson & Johnson
Bayer AG
Cardium Therapeutics
The Medicines Company
To order this report:
Therapy Industry: Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article